USE OF EXTENDED-RELEASE PRAMIPEXOLE IN EARLY-STAGE PARKINSON’S DISEASE: DESCRIPTION OF A CLINICAL CASE
https://doi.org/10.17650/1818-8338-2014-1-77-81
Abstract
The paper considers a clinical case of early-stage mixed Parkinson’s disease (PD) with significant affective disorders and restless legs syndrome. Once-daily extended-release pramipexole 3 mg significantly improved a patient’s status and led to regression of movement and affective disorders. The paper gives data on the efficacy of dopamine receptor agonists in treating PD and the benefits of their extended-release formulations.
About the Authors
N. V. Fedorova
Center of Extrapyramidal Diseases, Department of Neurology, Russian Medical Academy of Postgraduate Education, Ministry of Health of Russia, Moscow
Russian Federation
Russian Federation
Ye. N. Gubanova
Center of Extrapyramidal Diseases, Department of Neurology, Russian Medical Academy of Postgraduate Education, Ministry of Health of Russia, Moscow
Russian Federation
Russian Federation
References
1. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Parkinson Study Group. Clin Neuropharmaсol 2000;23(1):34–44.
2. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson’s disease: A randomized controlled trial. JAMA 2000;284(15):1931–8.
3. Corrigan M.H., Denahan A.Q., Wright C.E. et al. Comparison of pramipexole, fluoxetini, and placebo in patients with major depression. Depress Anxiety 2000;11(2):58–65.
4. Pogarell O., Gasser T., van Hilten J.J. et al. Pramipexole in patients with Parkinson’s disease and marked drug resistant tremor: a randomized, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry 2002;72(6):713–20.
5. Lemke M.R., Brecht H.M., Koester J. еt al. Anhedonia, depression, and motor functioning in Parkinson’s disease during treatment with pramipexole. J Neuropsychiatry Clin Neurosci 2005;17(2):214–20.
6. Lev N., Djaldetti R., Melamed E. Initiation of symptomatic therapy in Parkinson’s disease: dopamine agonists vs. levodopa. J Neurol 2007;254 suppl 5:19–26.
7. Iravani M.M., Haddon C.O., Cooper J.M. et al. Pramipexole protects against MPTP toxicity in non-human primates. J Neurochem 2006;96:1315–21.
8. Grosset K.A., Bone I., Grosset D.G. Suboptimal medication adherence in Parkinson’s disease. Mov Disord 2005;20(11):1502–7.
9. Grosset D., Antonini A., Caneci M. et al. Adherence to antiparkinson medication in a multicenter European study. Mov Disord 2009;24(6):826–32.
10. Earley C.J., Connor J.R., Beard J.L. et al. Abnormalities in CSF concentrations of ferritin and transferring in restless legs syndrome. Neurology 2000;54(8):1698– 700.
11. Левин О.С. Подходы к диагностике и лечению синдрома беспокойных ног. Трудный пациент 2009;4–5(7):4–10.
Review
For citations:
Fedorova N.V., Gubanova Ye.N. USE OF EXTENDED-RELEASE PRAMIPEXOLE IN EARLY-STAGE PARKINSON’S DISEASE: DESCRIPTION OF A CLINICAL CASE. The Clinician. 2014;8(1):77-81. (In Russ.) https://doi.org/10.17650/1818-8338-2014-1-77-81
Views:
1022
Email this article 